PDCD1 and small cell lung carcinoma: The ASTRUM-005 randomized clinical trial embarked upon a rigorous assessment of both the therapeutic efficacy and safety profile associated with the integration of the PD-1 inhibitor, serplulimab, into the standard chemotherapy regimen for first-line treatment in patients afflicted with ES-SCLC.